Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Evaluate Vantage Homepage
Pharmaceutical Companies
Dana-Farber Cancer Institute
February 26, 2019
A rare pancreatic cancer success, courtesy of a resurgent Lynparza
June 05, 2017
Asco – Aphinity and Roche’s 1% solution
April 18, 2016
AACR – Loxo and Ignyta clash on novel kinase mechanism
March 31, 2016
Interview – C4 starts life with a bang
September 25, 2015
ECC – Cometriq plays wallflower as Opdivo’s dance card fills
June 20, 2014
Upcoming events: Sanofi’s dermatitis biologic and readout from Novartis’s PI3K
December 09, 2013
ASH – Gazyva spearheads lymphoid malignancy revolution
June 04, 2013
Asco therapeutic focus – Spigot turned on melanoma agents
October 12, 2011
Therapeutic Focus - Pfizer grabs sickle cell therapy but novel approaches far off
March 22, 2011
Therapeutic focus – Cephalon buy points to rare win in small cell lung cancer
June 09, 2010
Asco - Eisai has convincing growth story in eribulin
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April
